Spero R Cataland

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi Immunotherapy for thrombotic thrombocytopenic purpura
    Spero R Cataland
    Departments of Internal Medicine and Pathology, Ohio State University College of Medicine and Public Health, Columbus, OH 43210 1240, USA
    Curr Opin Hematol 12:359-63. 2005
  2. ncbi Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, College of Medicine and Public Health, Columbus, Ohio 43210, USA
    Am J Hematol 83:911-5. 2008
  3. ncbi Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura
    Spero R Cataland
    Department of Medicine, Columbus, OH, USA
    Eur J Haematol 83:559-64. 2009
  4. ncbi Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 139:486-93. 2007
  5. ncbi Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
    Ming Jin
    Department of Pathology, College of Medicine, Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 141:651-8. 2008
  6. ncbi Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University College of Medicine and Public Health, Starling Loving Hall, Columbus, OH 43210, USA
    Expert Opin Pharmacother 8:437-44. 2007
  7. ncbi Leukocytoreduction for acute leukemia
    Pierluigi Porcu
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Ther Apher 6:15-23. 2002
  8. ncbi Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease
    Subha V Raman
    Division of Cardiovascular Medicine, The Ohio State University 473 W 12th Avenue, Suite 200, Columbus, OH 43210, USA
    Haematologica 91:1329-35. 2006
  9. ncbi Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
  10. ncbi Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura
    Spero R Cataland
    Department of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Am J Hematol 86:87-9. 2011

Collaborators

Detail Information

Publications13

  1. ncbi Immunotherapy for thrombotic thrombocytopenic purpura
    Spero R Cataland
    Departments of Internal Medicine and Pathology, Ohio State University College of Medicine and Public Health, Columbus, OH 43210 1240, USA
    Curr Opin Hematol 12:359-63. 2005
    ..This review focuses on recent advances in the use of immune-based therapy to treat patients with refractory and relapsing acquired thrombotic thrombocytopenic purpura...
  2. ncbi Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, College of Medicine and Public Health, Columbus, Ohio 43210, USA
    Am J Hematol 83:911-5. 2008
    ..These data support the hypothesis that prophylactic CSA improves the ADAMTS13 activity and may be effective at preventing relapses in patients at risk for recurrences of TTP...
  3. ncbi Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura
    Spero R Cataland
    Department of Medicine, Columbus, OH, USA
    Eur J Haematol 83:559-64. 2009
    ..We studied the clinical utility of demographic and ADAMTS13 biomarker data to predict the risk for exacerbation...
  4. ncbi Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 139:486-93. 2007
    ..These data suggest that the efficacy of CSA is at least in part related to its suppression of the antibody inhibitor of ADAMTS13 and a subsequent improvement in ADAMTS13 activity and antigen...
  5. ncbi Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
    Ming Jin
    Department of Pathology, College of Medicine, Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 141:651-8. 2008
    ..Identification of low ADAMTS13 activity during clinical remission as a key risk factor for TTP relapses provides a new screening strategy to identify patients who may benefit from prophylactic therapy prior to disease relapses...
  6. ncbi Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University College of Medicine and Public Health, Starling Loving Hall, Columbus, OH 43210, USA
    Expert Opin Pharmacother 8:437-44. 2007
    ..More recently, immunosuppressive therapy has been used alone as prophylactic therapy to prevent recurrences of acute TTP. This review focuses on the recent developments in the use of rituximab and ciclosporin in the treatment of TTP...
  7. ncbi Leukocytoreduction for acute leukemia
    Pierluigi Porcu
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Ther Apher 6:15-23. 2002
    ..The identification of the adhesion molecules, soluble cytokines, and chemotactic ligand-receptor pairs mediating endothelial cell damage in AHL should become a priority if better outcomes are desired...
  8. ncbi Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease
    Subha V Raman
    Division of Cardiovascular Medicine, The Ohio State University 473 W 12th Avenue, Suite 200, Columbus, OH 43210, USA
    Haematologica 91:1329-35. 2006
    ..This study sought to characterize myocardial characteristics in adult patients with SCD...
  9. ncbi Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  10. ncbi Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura
    Spero R Cataland
    Department of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Am J Hematol 86:87-9. 2011
    ..Further longitudinal study will be required to define the risk for neurologic injury and the long-term prognosis in patients previously diagnosed with TTP...
  11. ncbi An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura
    Spero R Cataland
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 136:146-9. 2007
    ..042). These data suggest that cyclosporin may have advantages over corticosteroids as an adjunct to PE therapy in the initial treatment of idiopathic TTP...
  12. ncbi Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura
    Spero R Cataland
    Department of Medicine, Ohio State University, Columbus, OH 43210, USA
    Semin Hematol 48:242-50. 2011
    ..The addition of these exciting new therapies to conventional plasma-based and/or immune modulating therapies provide hope for improved treatment outcomes for TTP patients...
  13. ncbi Rapid determination of ADAMTS13 activity improves clinical decision-making
    Spero R Cataland
    Am J Hematol 82:251. 2007